N@N

Oragenics To Present at the 6th Annual Rodman and Renshaw Global Investment Conference

^{Published on 2010-05-14 05:45:19 - Market Wire}
 

TAMPA, Fla.--([ BUSINESS WIRE ])--Oragenics, Inc. (OTCBB: ORNI) ([ www.oragenics.com ]), a biopharmaceutical company, announced today that it will be presenting at the Rodman & Renshaw 6th Annual Global Investment Conference on Tuesday, May 18th, in London. The conference will be held at the Grosvenor House Hotel. Oragenics will deliver its presentation at 3:40 PM GMT.

David Hirsch, the Company's CEO, will provide an overview of the Company's key technologies. Mr. Hirsch and Dr. Jeffrey Hillman, the Company's CSO, will be available for questions immediately following.

About Oragenics, Inc.

Oragenics, Inc. is a biopharmaceutical company engaged in the development of unique and novel proprietary technologies, derived from the study of oral biology. The Company's offerings include SMaRT^TM Replacement Therapy, a one-time treatment that provides a potential life-time prevention of dental caries (tooth decay), MU 1140, an antibiotic that has proven effective pre-clinically against Gram positive bacteria including MRSA, VRE and Clostridium, the DPOLT synthetic chemistry platform that enables the Company to produce MU 1140 and the other 49 known lantibiotics, and ProBiora3, a technology that whitens the teeth, freshens the breath and provides improved oral health. ProBiora3 is incorporated into the Company's three over-the-counter products: EvoraPlus ([ www.evoraplus.com ]), EvoraKids ([ www.evorakids.com ]) and Teddy's Pride ([ www.teddyspride.com ]). The company has offices located at 3000 Bayport Drive, Suite 685, in Tampa, Florida 33607, and in Progress Corporate Park at 13700 Progress Boulevard in Alachua, Florida 32615, approximately 15 miles from the campus of the University of Florida in Gainesville.